Rallybio Corp (RLYB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $88.03M
Last updated: Nov 17, 2026 at 4:15 PM ET
Rallybio Corp (RLYB) Statistics
Rallybio (RLYB) has a market cap of $88.03M. It kept 6177.42% of revenue as net income over the last 12 months. It holds $90.69M more cash than debt, 103.02% of its market cap.
Total Valuation
| Market Cap | $88.03M |
|---|---|
| Latest price (Nov 17, 2026) | $15.29 |
Key Dates
| Last Earnings Date | Oct 27, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 201.3x and 0.9x. Its year-end P/S ranged from 35.3x to 426.0x from 2023 to 2025.
| P/S Ratio | 201.3x |
|---|---|
| P/B Ratio | 0.9x |
| P/OCF Ratio | 2.8x |
Price Statistics
The stock is up 453.14% over 52 weeks and trades 48.02% above its 50-day average.
| Beta (1Y) | 1.07 |
|---|---|
| 52-Week Change | +453.14% |
| 1-Month Change | +73.27% |
| 3-Month Change | +66.64% |
| 6-Month Change | +99.64% |
| 5-Year Change | -89.12% |
| Total Return (1Y) | +943.70% |
| Total Return (3Y CAGR) | +21.18% |
| Total Return (5Y CAGR) | -22.75% |
| Return vs SPY (1Y) | +453.77% |
| Max Drawdown (1Y) | -31.05% |
| Max Drawdown (3Y) | -92.33% |
| Sharpe Ratio (1Y) | 1.81 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $10.33 |
| 200-Day Average | $7.68 |
| 52-Week Range | $3.67 to $17.57 |
| RSI (14 Days) | 78.9 |
| Average Volume (20 Days) | 34.90K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 28.87x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 28.87x |
|---|---|
| Quick Ratio | 28.87x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 29.05% over the last 12 months, against a 5-year average of -49.11%.
| Return on Equity (ROE) | 29.05% |
|---|---|
| Return on Assets (ROA) | 28.05% |
| ROE (5Y Average) | -49.11% |
| ROA (5Y Average) | -45.30% |
| ROIC (5Y Average) | -14.03% |
| Asset Turnover | 0.01x |
Taxes
Income tax took 4.98% of pretax income over the last 12 months.
| Income Tax (TTM) | $1.40M |
|---|---|
| Effective Tax Rate | 4.98% |
Scores
RLYB has an Altman Z-Score of 14.09, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 14.09 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $434.00K over the last 12 months is down 35.61% from the 12 months before.
| Revenue | $434.00K |
|---|---|
| Revenue Growth (YoY) | -35.61% |
| Gross Profit | $434.00K |
| Operating Income | -$24.22M |
| Pretax Income | $28.21M |
| Net Income | $26.81M |
| Reported EPS (TTM) | -$4.55 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 96.57% of the $95.58M in total assets.
| Cash and Equivalents | $90.69M |
|---|---|
| Total Debt | $0 |
| Net Cash | $90.69M |
| Net Cash Per Share | $15.87 |
| Working Capital | $91.49M |
| Shareholder Equity | $92.30M |
| Book Value Per Share | $16.15 |
| Total Assets | $95.58M |
| Total Liabilities | $3.28M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $30.99M |
|---|---|
| FCF Per Share | $5.83 |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -5580.88%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -5580.88% |
| Pretax Margin | 6500.92% |
| Net Margin | 6177.42% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -27.56% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -27.56% |
Dividends and Yields
RLYB does not pay a dividend.
| Buyback Yield | -0.02% |
|---|---|
| Shareholder Yield | -0.02% |
Stock Splits
The last split was a 1-for-8 reverse split on Feb 6, 2026.
| Last Split Date | Feb 6, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:8 |
Peer Position
Against 7 similar companies, RLYB has the highest P/S.
P/S RatioPeer median 16.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -42.77%
| P/S Ratio | 201.3x vs 16.9x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -35.61% vs -42.77% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RLYB
What is RLYB's market cap?
Rallybio has a market cap of $88.03M.
How many shares of RLYB are outstanding?
Rallybio has 5.72M shares outstanding. The count is up 1.47% from a year earlier.
Does RLYB pay a dividend?
No. Rallybio does not pay a dividend.
How much debt does RLYB have?
Rallybio has $0 of total debt and $90.69M of cash and equivalents, a net cash position of $90.69M.
RLYB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors